Hungarian Immunology

[Regional cues and phenotypic responses during the ontogeny and postnatal development of splenic vasculatur]

BALOGH Péter

JANUARY 30, 2006

Hungarian Immunology - 2006;5(01)

[Among structured peripheral lymphoid tissues in man and rodents, the spleen demonstrates the most extensive flexibility in functional activities, which is coupled with considerable tissue architecture adjustments during ontogeny and immune reactions. The sequential conversion of a primary lymphohemopoietic tissue into a major peripheral lymphoid organ (while participating in the post-myeloid period of primary B-lymphopoiesis and retaining the potential for myelopoiesis) is accompanied with the ordered segregation involving various non-hemopoietic components of architecture, including the endothelia of blood vessels. In this report we will survey the functional and structural aspects of heterogeneous endothelial cells lining the various splenic vascular beds, comprising the complex circulatory network of the spleen. These features will be correlated with the characteristics of those regulatory mechanisms that have recently been demonstrated to be responsible for the establishment and maintenance of the endothelial divergence during splenic vascular development, including crucial transcription factors, morphogenic regulatory ligands and receptors of the tumor necrosis factor/lymphotoxin (TNF/LT) family and others. The influence of these regulatory elements in mice appears to be highly restricted in terms of regional involvement of the vasculature, with cellular alterations of the marginal sinus representing the most frequently affected region. This complexity highlights the importance of this tissue region in both the formation of splenic vasculature and a possible source for white pulp stromal elements as well as its function as a major gateway for lymphocyte traffic.]

COMMENTS

0 comments

Further articles in this publication

Hungarian Immunology

[Primer and transitory defects of interferonactivated pathways]

ERDŐS Melinda, MARÓDI László

Hungarian Immunology

[Natural immunity]

SZEGEDI Gyula

Hungarian Immunology

[About the genetics of autoimmune diseases]

SZEGEDI Gyula

Hungarian Immunology

[Congress of the American College of Rheumatology, 2005]

SZŰCS Gabriella, SZÁNTÓ Sándor

Hungarian Immunology

[Antiphospholipid syndrome - focused on the childhood form]

KÁLOVICS Tamás, PONYI Andrea, BENSE Tamás, MÜLLER Judit, DANKÓ Katalin, FEKETE György, CONSTANTIN Tamás

[Antiphospholipid syndrome is an autoimmune disorder characterized by recurrent thromboembolic events with concurrent presence of antiphospholipid antibodies in the sera. The morbidity and mortality of the syndrome is defined by the clinical manifestations: deep vein thrombosis, cerebrovascular events, myocardial infarct, pulmonary embolism, recurrent pregnancy losses and prematurity. The authors reviewed the pathogenesis, the clinical course and the treatment of the antiphospholipid syndrome focused on the childhood form.]

All articles in the issue

Related contents

Clinical Neuroscience

[EFFECTS OF KETAMINE ON THE DEVELOPING CENTRAL NERVOUS SYSTEM]

VUTSKITS László, GASCON Eduardo, KISS Zoltán József

[Ketamine is a widely used drug in pediatric anesthesia practice, acting primarily through the blockade of the Nmethyl- D-aspartate (NMDA) type of glutamate receptors. A growing body of laboratory evidence, accumulated during the past few years, suggests that this drug could have potential adverse effects on the developing central nervous system. The goal of this short review is to give a brief synopsis of experimental work indicating ketamine-induced developmental neurotoxicity as well as to discuss potential limitations concerning extrapolation of these studies to clinical practice.]

Hypertension and nephrology

[Hypertension and menopause]

MASSZI Gabriella

Clinical Oncology

[Biomarkers - today and tomorrow]

KOPPER László

[Biomarkers (tumor markers in oncology) are able to make exact, objective and reproducible distinction between two groups. Biomarkers can serve different purposes, as to estimate the patient’s survival without treatment (prognostic marker), to select those patients who would respond optimally to treatment (predictive marker), to follow the patient in order to detect of a relapse (monitoring marker), helping identifi cation the tumor-type (diagnostic marker). The main task for a biomarker is to find the best treatment with less toxicity. The main enemy of biomarkers is the heterogeneity of the tumor, the continuous change in its geno- and phenotype, which can explain the low sensitivity and specifi city. More attention should be given to standardization and validity. It is highly possible, that biomarker-panel as well as marker-based clinical trials will be used in the near future.]

Clinical Neuroscience

[POSTNATAL EXPRESSION PATTERN OF DOUBLECORTIN (DCX) IN SOME AREAS OF THE DEVELOPING BRAIN OF MOUSE]

TAKÁCS József, ROBERTA Zaninetti, VÍG Julianna, VASTAGH Csaba, HÁMORI József

[We have investigated the spatio-temporal expression pattern of doublecortin (DCX) protein from postnatal day (P) 2 to postnatal day (P) 22 in the brain of developing mouse. We compared the expression of DCX in the rostral migratory stream (RMS) and dentate gyrus of the hippocampus (DG). Weak expression of DCX was detected in the RMS at P5, it became gradually stronger during the second postnatal week and reached its strongest expression by P18-P22. Moderate DCX immunostaining was present in the DG at P11, its marked expression - characteristic of newly generated neurons in the adult DG - appeared only after P22. Morphological and functional maturation was different in the RMS and DG, continuous neurogenesis appeared earlier in the RMS than in the DG.]

Lege Artis Medicinae

[ENDOTHELIUM PROTECTION IN HYPERTENSIVE PATIENTS]

KÉKES Ede

[The author presents a review about the fundamental principles of normal endothelial function and the main causes for the development of endothelial dysfunction. First of all, endothelial dysfunction results in structural alterations in the wall of the vessel - the „vascular remodelling” in hypertension - and that is the base of hypertensive microangiopathy and target organ damage. In patients with high blood pressure the reactivity of vessels is impaired by the endothelial dysfunction. The members of the main drug groups can influence the vasoactive factors produced in endothelium differently. This different effects of drugs create different clinical benefits. Especially, the ACE inhibitors, the calcium antagonists (mostly the new generation of dihydropyridines) have endothelial protective effects, but some β-blockers, α-1 adrenergic blockers and - in a totally different way of action - the statins are capable of influencing the endothelial dysfunction.]